Galleri MCED Test Fails to Meet Primary Endpoint in Large Trial.
- In the news
GRAIL's Galleri MCED test did not significantly reduce late-stage cancers in a large NHS-Galleri trial, with only a modest improvement observed in stage IV cases.
- Why it matters: Early detection of cancer is crucial for improving patient outcomes, but current screening methods lack broad effectiveness across multiple cancer types, creating a need for better tools.
- What they did: The NHS-Galleri trial evaluated over 140,000 participants using the Galleri test, aiming to lower the incidence of stage III and IV cancers through early detection.
- The result: The trial's results indicate that Galleri did not meet its primary endpoint, suggesting limited clinical benefit and challenging its widespread adoption for cancer screening.